DSCD lenses significantly reduce spherical equivalent refraction (SER) progression and axial length (AL) elongation in myopic children over 12 months, outperforming single-vision spectacles (SVS) and single-surface defocus (SSD) lenses.
In exploratory analyses, DSCD efficacy is pronounced in children aged 8-12 years, with baseline AL 24-25 mm and low myopia, highlighting potential subgroup targeting.
Comparable spectacle-based interventions, including cylindrical annular refractive elements (CARE) and extended depth-of-focus (EDOF) lenses, also demonstrate robust myopia control, supporting peripheral defocus as a key mechanistic modality.
DSCD lenses show excellent safety, high compliance, and good tolerability, positioning them as a viable option for pediatric myopia management alongside pharmacologic and ortho-k therapies.
